Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Relay Therapeutics, Inc. (RLAY)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
22.45+0.32 (+1.45%)
At close: 04:00PM EDT
22.45 0.00 (0.00%)
After hours: 04:47PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close22.13
Open21.58
Bid21.77 x 900
Ask30.00 x 1400
Day's Range21.38 - 22.74
52 Week Range12.65 - 38.15
Volume1,493,294
Avg. Volume1,226,834
Market Cap2.426B
Beta (5Y Monthly)1.44
PE Ratio (TTM)N/A
EPS (TTM)-2.84
Earnings DateMar 23, 2022 - Mar 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.88
  • GlobeNewswire

    Relay Therapeutics Announces Pricing of Public Offering of Common Stock

    CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwritten public offering of 11,320,755 shares of its common stock at a public offering price of $26.50 per share. Relay Therapeutics also granted the underwriters a 30-day option to purchase up to an additional 1,

  • GlobeNewswire

    Relay Therapeutics Announces Proposed Public Offering of Common Stock

    CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced an underwritten public offering of $300.0 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of t

  • Business Wire

    Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOne®CDx as a Companion Diagnostic for Relay’s Investigational FGFR2 Inhibitor, RLY-4008

    CAMBRIDGE, Mass., September 12, 2022--Today Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, and Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced a collaboration to develop FoundationOne®CDx as a companion diagnostic for RLY-4008, the company’s investigational FGFR2 inhibitor.

Advertisement
Advertisement